Beroni Group Limited, together with its subsidiaries, develops and sells smoking control products, air purifier, water filter, healthcare products and supplements, cell therapies, stem-cell based cosmetics, and viral diagnostic kits in China. It operates through four segments: Cell Therapies; Developing New Anti-Cancer Drugs; E-commerce Platform for Pharmaceutical and Healthcare Products; and Detection & Diagnosis of Infectious Diseases. The company offers NicoBloc, a smoking cessation/harm reduction product; SARS-CoV-2 IgG/IgM antibody detection kit; COVID-19 Antigen Rapid Test Kit; Bei Feiqing Tablet Candy, Bei Jingli Tablet Candy, and Beilemei freeze-dried powder; and cosmetic products, such as V show rejuvenation liquid, hyaluronic acid moisturizing silk mask, and avocado poly-peptide intensive treatment silk mask. It also provides CII-ArboViroPlex rRT-PCR assay that detects zika, dengue, chikungunya, and west nile viruses; stem cell cosmetics products comprising AGG Skin-Smoothing and Anti-Wrinkle Facial Mask, AGG Skin-Smoothing and Anti-Wrinkle Sample Pack, ODd Skin Repair Essence, AGG Skin-Smoothing and Anti-Wrinkle Essence, and ODd Beroni Beauty Facial Mask; and cardiology, hepatology, and oncology and immunotherapy solutions. In addition, the company offers cell therapies for cancer treatment; research on the treatment of cancer, as well as development of targeted therapies, immunotherapies, cancer vaccines, chemotherapy, radiation therapy, and surgery; and provides e-commerce platform for pharmaceutical and healthcare products. Further, it provides fogibloc air purifier and olansi water filter products. Beroni Group Limited was founded in 2014 and is headquartered in Sydney, Australia.
Moat, DCF and rating computed by our valuation engine (ported from the original Python model).